
Lưu ý: Hình bìa chỉ mang tính minh họa — không phải ảnh sách thực tế. Nội dung và bản quyền sách được đảm bảo chính hãng từ nhà xuất bản. Chợ Sách chỉ cam kết sách do người bán cung cấp là sách chính hãng; khiếu nại về bìa khác hình minh họa sẽ được xem xét từng trường hợp.
Tác giả: Sanjay J. Mathew, Carlos A. Zarate Jr.
NXB: Adis
Chi tiết sản phẩm
Thông tin sách: Ketamine for Treatment-Resistant Depression: The First Decade of Progress (Kindle, 174 trang) – Adis, 2016. Ngôn ngữ: Tiếng Anh.
This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants.
Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic moleculartargets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose.
This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
Giá bán
Liên hệ
0Alain C. Masquelet
12.291.000 ₫
0Christopher Madden MD FACSM, Margot Putukian MD FACSM, Eric McCarty MD, Craig Young MD
2.779.000 ₫
0Michael J. Aminoff MD DSc FRCP, Ted Burns MD
6.192.000 ₫
0B. J. Manaster MD PhD FACR, Julia Crim MD
9.380.000 ₫
0Cree M. Gaskin, MD MBA S. Lowell Kahn, J. Christoper Bertozzi, Paul M. Bunch
14.118.000 ₫
0Tim D. White, Michael T. Black, Pieter A. Folkens
2.949.000 ₫
3.276.000 ₫
0Juergen K Mai, Milan Majtanik, George Paxinos AO (BA MA PhD DSc) FASSA FAA
7.554.000 ₫
8.194.000 ₫
0Anne M Gilroy, Brian R MacPherson, Michael Schuenke, Erik Schulte, Udo Schumacher
2.298.000 ₫
2.720.000 ₫
0Anne M. R. Agur BSc(OT) MSc PhD, Arthur F. Dalley II PhD FAAA
2.950.000 ₫
0Anna P. Henderson
5.900.000 ₫
0Anne M. R. Agur BSc (OT) MSc PhD FAAA, Arthur F. Dalley II PhD FAAA
2.528.000 ₫
0Ralf J Radlanski, Karl H Wesker
5.834.000 ₫
Mua từ người bán đáng tin cậy trên Chợ Sách
5–16 ngày
XL 2 ngày + VC 3–14 ngày
Liên hệ
0Bạn có cuốn này? Kiếm tiền bằng cách bán lại.
Bán ngay →